|

JANX007 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Pipeline

Phase 1: 2

Top Sponsors

  • Janux Therapeutics2

Indications

  • Prostate Cancer2
  • Cancer2
  • Castration-Resistant Prostate Cancer (CRPC)1
  • Castration-Resistant Prostatic Cancer1
  • Metastatic Castration-Resistant Prostate Cancer Patients1

Birmingham, Alabama1 trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

University of Alabama at Birmingham Hospital

Phase 1

Nashville, Tennessee1 trial

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

Sarah Cannon Research Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.